Evidence mapPaperPMID 39200247Full record

ArticleBiomedicines2024

Prognostic Value of High-Density Lipoprotein Cholesterol in Patients with Overt Hepatic Encephalopathy.

Ke Shi, Yufei Bi, Xiaojing Wang, Yanqiu Li, Xuanwei Zeng, Ying Feng, Xianbo Wang

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke ShiCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yufei BiCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xiaojing WangCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yanqiu LiCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xuanwei ZengCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Ying FengCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xianbo WangCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.ORCID 0000-0002-3593-5741

Funding

Beijing Municipal Natural Science Foundation 7232272Beijing Traditional Chinese Medicine Technology Development Fund Project BJZYYB-2023-06Capital health development research project 2024-1-2173high-level Chinese Medicine Key Discipline Construction Project zyyzdxk-2023005National Natural Science Foundation of China 82004153Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University CCMU2022ZKYXY015
6 · The paper itself

Abstract

Overt hepatic encephalopathy (OHE), a serious complication of liver cirrhosis, is associated with alterations in lipid and lipoprotein metabolism. We evaluated the correlation between high-density lipoprotein cholesterol (HDL-C) levels and transplant-free (TF) mortality in patients with OHE. Patients with OHE admitted to Beijing Ditan Hospital between January 2010 and August 2016 (n = 821) and between September 2016 and December 2020 (n = 480) were included in the training and validation sets, respectively. Independent predictors were explored by a multivariate Cox regression analysis, and the area under the receiver operating characteristic curve (AUC) was used to assess the prognostic value of these factors. The prognostic value of HDL-C was good (AUC at 1 year: 0.745) and was equivalent to that of the Model for End-Stage Liver Disease (MELD) score (AUC at 1 year: 0.788). The optimal threshold values for HDL-C and MELD were 0.5 mmol/L and 17, respectively. The 1-year TF mortality rates in the low-risk (HDL-C ≥ 0.5 mmol/L and MELD < 17) and high-risk (HDL-C < 0.5 mmol/L and MELD ≥ 17) groups were 7.5% and 51.5% in the training set and 10.1% and 48.2% in the validation set, respectively. HDL-C level < 0.5 mmol/L and MELD score > 17 can facilitate the identification of high-risk patients and provide a basis for timely treatment.

Indexed as

hepatic encephalopathyhigh-density lipoprotein cholesterolprognosistransplant-free mortality

Identifiers

PMID39200247
PMCPMC11351328

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.